Treatment for Bone Metastasis in CRPC - Practical Management for Patient Selection VL

Real-World Safety and Effectiveness of Radium-223 in Japanese Patients with Castration-Resistant Prostate Cancer (CRPC) and Bone Metastasis - Beyond the Abstract

Details
Real-World Safety and Effectiveness of Radium-223 in Japanese Patients with Castration-Resistant Prostate Cancer (CRPC) and Bone Metastasis: Exploratory Analysis, Based on the Results of Post-Marketing Surveillance, According to Prior Chemotherapy Status - Beyond the Abstract Biographies: Hirotsugu Uemura, Urologist, Chief Professor, Urology Department, Kindai University, Japan Related Content: Re...

Radium-223 Treatment for Metastatic Prostate Cancer - Ila Sethi

Details
As part of this patient-centered video series of lectures on prostate cancer diagnosis and treatment, Dr Sethi presents the timing for radium-223 treatment in mCRPC. She details who qualifies as a candidate for radium 223 therapy, how it is given, the limited side effects of this treatment, that PSA is not a biomarker for treatment success and other treatment management considerations. Biography:...

The NCCN Guidelines on the Use of Radium-223 in Prostate Cancer - Tanya Dorff

Details
In this conversation Tanya Dorff and Alicia Morgans discuss the guidance coming from the NCCN on the use of radium-223 in the metastatic castration-resistant prostate cancer setting, including choosing the right patient for this drug, factors to consider, and the timing of this therapy. As lines of therapy become more complicated with many castration-resistant drugs moving to the hormone-sensitive...

Patient Assessment and Treatment Strategies for mCRPC - William Oh

Details
William Oh joins Alicia Morgans in a discussion on the management and treatment options for patients progressing on treatment to mCRPC. Drs. Morgans and Oh discuss the challenging decisions for optimal patient selection, counseling our patients who are receiving radium, the timing of treatment, supportive management around the use of radium, and its side effects. Biographies: William Oh, MD Chief...

Optimal Patient Selection for Treatment with Radium-223 in mCRPC Towards Improved Overall Survival and Improved Quality of Life - Brenda Martone

Details
Brenda Martone and Alicia Morgans discuss the positioning of radium-223 in the treatment of patients with bone-only mCRPC. Brenda emphasizes that radium-223 is approved for symptomatic bone-only disease and that this includes many symptoms including fatigue, loss of appetite, and others that are not limited to bone-related pain. This is approved in a broad population and needs to be considered in...

The Importance of Bone-Protecting Agents When Treating mCRPC with Bone Metastatic Disease The PEACE III Trial – Silke Gillessen

Details
In this conversation with Alicia Morgans, Silke Gillessen highlights the bone health analysis evaluating the combination of enzalutamide and radium or enzalutamide alone might affect bone health and fracture rate within patients with metastatic castration-resistant prostate cancer. At the 2021 ASCO meeting, Dr. Gillessen presented an updated safety analysis from the EORTC 1333 / PEACE III trial of...

The Effect of Mandated Bone Protective Agents on Fracture Risk With Longer Follow-Up (EORTC 1333 / PEACE III Trial) – Fred Saad

Details
Bone strengthening agents such as bisphosphonates or the RANKL-targeting antibody denosumab reduced the bone loss associated with androgen deprivation therapy (ADT) and prevent skeletal-related events in castration resistant prostate cancer (CRPC). The use of these agents is recommended in CRPC by many guidelines. The randomized phase III EORTC-1333-GUCG also known as the PEACE-III trial, compares...